AI-generated content for informational purposes only. Not financial advice. Always do your own research.

Over

Telegezondheidsplatform dat gepersonaliseerde gezondheids- en welzijnsoplossingen biedt voor mannen en vrouwen, waaronder behandelingen op het gebied van dermatologie, geestelijke gezondheid, seksuele gezondheid en gewichtsbeheer.

Small-cap groeiaandelen

Hims & Hers is een snel groeiend telehealth-platform dat gepersonaliseerde wellnessoplossingen biedt voor haaruitval, huidverzorging, seksuele gezondheid en mentale gezondheid via een direct-to-consumer-model.

Key Financials HIMS

Prijs $16.30
Wijziging (1D) +3.16%
Wijziging (30D) -49.80%
Wijziging (60D) -54.19%
Wijziging (90D) -70.23%
Wijziging (180D) -69.44%
Wijziging (1Y) -64.83%
Wijziging (5Y) -30.64%
P/E-verhouding 20.63
EPS (TTM) $0.79
52-weekse bandbreedte $15.63 — $72.98
50-daags MA $31.23
Volume 26.12M

Data updated Feb 15 · Source: Twelve Data

2.8
1 reviews
Valuation
3.2
Fundamentals
3
Management Quality
2.8
Performance
2.2
Risk Profile
2
Claude Opus 4.6
AI Review
2.8/5

Hims & Hers Health operates a telehealth platform offering personalized health and wellness products, primarily in men's and women's health categories including hair loss, sexual health, and skincare. The company has demonstrated strong revenue growth and achieved profitability, with a TTM EPS of $0.79 and a now-reasonable P/E of 20.63 following a dramatic selloff.

The stock has experienced a devastating decline of over 70% from its 52-week high of $72.98, largely driven by regulatory concerns around compounded GLP-1 medications (semaglutide) and FDA actions that threaten a significant revenue stream. Trading well below its 50-day moving average of $31.23, the technical picture is deeply bearish.

Bull case: The core telehealth platform remains viable with a loyal subscriber base, the valuation is now compelling for a growth company, and management has diversified product offerings. Bear case: GLP-1 regulatory headwinds could materially impact revenue projections, competitive pressures from traditional healthcare providers are intensifying, and the stock may need time to find a floor. The elevated volume suggests ongoing institutional repositioning. This is a high-risk, potentially high-reward situation best suited for investors with strong conviction and patience.

Valuation
3.2
Fundamentals
3
Management Quality
2.8
Performance
2.2
Risk Profile
2
Feb 15, 2026
Hims & Hers Health Screenshot

Added: Feb 15, 2026

forhims.com

Latest from Otrai